Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):S79-87.

Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies.

Author information

  • 1Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143-1207, USA. aboxer@memory.ucsf.edu

Abstract

Frontotemporal dementia (FTD) is a common cause of dementia that encompasses 3 clinical subtypes: a behavioral/dysexecutive (frontal) variant and 2 variants with prominent language impairments. There are currently no Food and Drug Administration-approved medications for FTD although symptomatic treatments such as selective serotonin reuptake inhibitors and atypical antipsychotic agents are frequently used to manage behavioral abnormalities associated with this disorder. Evidence for the use of currently available symptomatic treatments in each FTD clinical subtype is reviewed. In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed.

PMID:
18090429
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk